J S Glenn

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc A prenylation inhibitor prevents production of infectious hepatitis delta virus particles
    Bruno B Bordier
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    J Virol 76:10465-72. 2002
  2. pmc Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing
    Dan Xu
    Department of Anesthesia, Stanford University School of Medicine, Stanford, California, United States of America
    PLoS Med 11:e1001628. 2014
  3. pmc Simplified RNA secondary structure mapping by automation of SHAPE data analysis
    Phillip S Pang
    Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA
    Nucleic Acids Res 39:e151. 2011
  4. pmc The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy
    Phillip S Pang
    Department of Medicine, Division of Infectious Diseases and Geographic Medicine and Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA
    PLoS ONE 4:e6579. 2009
  5. pmc Structural map of a microRNA-122: hepatitis C virus complex
    Phillip S Pang
    Department of Medicinea and Protein and Nucleic Acid Facility, Stanford University School of Medicine, Stanford, California, USA
    J Virol 86:1250-4. 2012
  6. ncbi request reprint Hepatitis d
    Elif S Koytak
    Jeffrey S Glenn, MD, PhD Division of Gastroenterology and Hepatology, CCSR Building, Room 3115A, Stanford University School of Medicine, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    Curr Treat Options Gastroenterol 10:456-63. 2007
  7. ncbi request reprint Prenylation of HDAg and antiviral drug development
    J S Glenn
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
    Curr Top Microbiol Immunol 307:133-49. 2006
  8. ncbi request reprint Novel therapies for hepatitis C virus based on lessons from virology
    Jeffrey S Glenn
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
    Clin Gastroenterol Hepatol 3:S86-8. 2005
  9. ncbi request reprint Molecular virology of the hepatitis C virus: implication for novel therapies
    Jeffrey S Glenn
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine and Palo Alto Veterans Administration Medical Center, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    Clin Liver Dis 9:353-69, v. 2005
  10. pmc Use of a prenylation inhibitor as a novel antiviral agent
    J S Glenn
    Division of Gastroenterology, Stanford University School of Medicine and Veterans Administration Medical Center, Palo Alto, California 94305 5487, USA
    J Virol 72:9303-6. 1998

Research Grants

Collaborators

  • Patricia L Marion
  • Paul J Planet
  • Cihan Yurdaydin
  • CHARLES M contact RICE
  • S Pfeffer
  • John L Casey
  • Menashe Elazar
  • Phillip S Pang
  • Bruno B Bordier
  • Shirit Einav
  • Ella H Sklan
  • Dan Xu
  • Edward A Pham
  • Ping Liu
  • Elif S Koytak
  • Nam Joon Cho
  • Tsafi Danieli
  • Benjamin Aroeti
  • Kwang Ho Cheong
  • Meirav Matto
  • Kazuo Ohashi
  • Harry B Greenberg
  • Mark A Kay
  • Gary Peltz
  • Marylin Masek
  • Toshi Nishimura
  • Sara A Michie
  • Ming Zheng
  • Ying Ying Guo
  • Haili Zhang
  • Sachiko Nishimura
  • Shripa G Patel
  • Michael R Eckart
  • Ramon L Serrano
  • Tina M Oakes
  • Mark Winters
  • Curtis W Frank
  • David G Lambright
  • Choongho Lee
  • Kirk Staschke
  • F H Salazar
  • So Young Lee
  • Andrew D Hamilton
  • Leonard Meuse
  • Said M Sebti
  • Junko Ohkanda

Detail Information

Publications21

  1. pmc A prenylation inhibitor prevents production of infectious hepatitis delta virus particles
    Bruno B Bordier
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    J Virol 76:10465-72. 2002
    ..Farnesyltransferase inhibitors thus represent an attractive potential class of novel antiviral agents for use against HDV, including the genotypes associated with most severe disease...
  2. pmc Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing
    Dan Xu
    Department of Anesthesia, Stanford University School of Medicine, Stanford, California, United States of America
    PLoS Med 11:e1001628. 2014
    ..Therefore, we investigated whether FIAU-induced liver toxicity could be detected in chimeric TK-NOG mice with humanized livers...
  3. pmc Simplified RNA secondary structure mapping by automation of SHAPE data analysis
    Phillip S Pang
    Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA
    Nucleic Acids Res 39:e151. 2011
    ..In conclusion, FAST allows for high-throughput data processing to match the current high-throughput generation of data possible with SHAPE, reducing the barrier to determining the structure of RNAs of interest...
  4. pmc The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy
    Phillip S Pang
    Department of Medicine, Division of Infectious Diseases and Geographic Medicine and Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA
    PLoS ONE 4:e6579. 2009
    ..Given that interferon therapy functions by triggering an immune response, we hypothesized that clinical response rates are a reflection of viral evolutionary adaptations to the immune system...
  5. pmc Structural map of a microRNA-122: hepatitis C virus complex
    Phillip S Pang
    Department of Medicinea and Protein and Nucleic Acid Facility, Stanford University School of Medicine, Stanford, California, USA
    J Virol 86:1250-4. 2012
    ..These additional interactions enhance HCV replication in cell culture. To our knowledge, this is the first biophysical study of this complex to reveal the importance of 'tail' miR-122 nucleotide interactions...
  6. ncbi request reprint Hepatitis d
    Elif S Koytak
    Jeffrey S Glenn, MD, PhD Division of Gastroenterology and Hepatology, CCSR Building, Room 3115A, Stanford University School of Medicine, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    Curr Treat Options Gastroenterol 10:456-63. 2007
    ..The only approved therapy for chronic hepatitis D is interferon-alpha. Although transplantation offers a safe therapeutic option for managing end-stage HDV disease, novel therapeutic approaches are urgently needed...
  7. ncbi request reprint Prenylation of HDAg and antiviral drug development
    J S Glenn
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
    Curr Top Microbiol Immunol 307:133-49. 2006
    ..These agents represent a new class of antiviral agents, with HDV as a first target. Here, a brief review of the HDV life cycle emphasizing the role of prenylation is presented along with implications for drug development and therapy...
  8. ncbi request reprint Novel therapies for hepatitis C virus based on lessons from virology
    Jeffrey S Glenn
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
    Clin Gastroenterol Hepatol 3:S86-8. 2005
    ..As a result, the way we treat HCV should change dramatically over the next few years...
  9. ncbi request reprint Molecular virology of the hepatitis C virus: implication for novel therapies
    Jeffrey S Glenn
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine and Palo Alto Veterans Administration Medical Center, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    Clin Liver Dis 9:353-69, v. 2005
    ..This should minimize the emergence of resistance against any single agent. The way we treat HCV should change dramatically over the next few years...
  10. pmc Use of a prenylation inhibitor as a novel antiviral agent
    J S Glenn
    Division of Gastroenterology, Stanford University School of Medicine and Veterans Administration Medical Center, Palo Alto, California 94305 5487, USA
    J Virol 72:9303-6. 1998
    ..These results demonstrate that the use of such a prenylation inhibitor-based antiviral therapy may be feasible and identify a novel class of potential antiviral agents...
  11. pmc In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus
    Bruno B Bordier
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California 94305, USA
    J Clin Invest 112:407-14. 2003
    ..These results provide the first preclinical data supporting the in vivo efficacy of prenylation inhibition as a novel antiviral therapy with potential application to HDV and a wide variety of other viruses...
  12. ncbi request reprint Prenylation inhibitors: a novel class of antiviral agents
    Shirit Einav
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
    J Antimicrob Chemother 52:883-6. 2003
    ....
  13. pmc An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication
    Menashe Elazar
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    J Virol 78:11393-400. 2004
    ..These results identify a key membrane-targeting domain which can form the basis for developing novel antiviral strategies...
  14. ncbi request reprint Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitors
    Bruno B Bordier
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine and Veterans Administration Medical Center, Palo Alto, CA, USA
    Methods Mol Med 96:539-53. 2004
  15. pmc Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes
    Nam Joon Cho
    Department of Materials Science and Engineering, Stanford University, 381 North South Mall, Stauffer III, Stanford, CA 94305, USA
    J Virol 81:6682-9. 2007
    ..These results also demonstrate the successful development of a new nanosensor technology ideal both for studying the interaction between a protein and its target membrane and for developing inhibitors of that interaction...
  16. ncbi request reprint TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication
    Ella H Sklan
    Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305 5187, USA
    J Biol Chem 282:36354-61. 2007
    ..These results highlight a novel mechanism by which viruses can hijack host cell machinery and suggest an attractive model whereby the NS5A-TBC1D20 interaction may promote viral membrane-associated RNA replication...
  17. ncbi request reprint Overdependence on the host-an Achilles' heel of HCV?
    Jeffrey S Glenn
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA
    Hepatology 39:1734-5. 2004
  18. pmc A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication
    Shirit Einav
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    J Virol 78:11288-95. 2004
    ..Genetically disrupting the NBM impairs GTP binding and hydrolysis and dramatically inhibits HCV RNA replication. These results have exciting implications for the HCV life cycle and novel antiviral strategies...
  19. pmc Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication
    Menashe Elazar
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California 94305, USA
    J Virol 77:6055-61. 2003
    ..Moreover, an AH peptide-mimic inhibits the membrane association of NS5A in a dose-dependent manner. These results have exciting implications for the HCV life cycle and novel antiviral strategies...
  20. pmc Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts
    Meirav Matto
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR Building, Room 3115, 269 Campus Dr, Palo Alto, CA 94305 5187, USA
    J Virol 78:12047-53. 2004
    ..These results may have broad implications for the HCV life cycle and suggest that the HCV core may be a valuable probe for host cell biology...
  21. pmc A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication
    Ella H Sklan
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR 3115A, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    J Virol 81:11096-105. 2007
    ..These results suggest that pharmacologic disruption of this NS5A-interacting partner can be contemplated as a potential new antiviral strategy against a pathogen affecting nearly 3% of the world's population...

Research Grants2

  1. HCV NS4B: Translating molecular virology into novel antiviral therapies
    Jeffrey S Glenn; Fiscal Year: 2010
    ....
  2. HCV NS5A: Molecular Virology and Antiviral Target
    Jeffrey S Glenn; Fiscal Year: 2010
    ..We will use phage display to identify high affinity random peptide ligands of the AH. Finally, we will explore how our results can be translated into novel anti-HCV strategies. ..